Author Archives: Bruno Quinney

Immunotherapy
#AI #Drug discovery #Immunotherapy #Multi-omics #T cell engagers

How tech and collaboration are accelerating the development of T-cell engagers

Alistair Henry, Executive Vice President Chief Scientific Officer at UCB, explains that various factors that are helping drive the development of T-cell engagers (TCEs).  Why is immunotherapy discovery constantly evolving?   As scientists, we are trained to measure, analyse and interpret. We quantify binding affinities, map pathways, and build increasingly sophisticated models of disease. Read More

#Exclusive Content

#Clinical trial #DDII #Drug discovery #Immunology / Virology & Vaccines #Lung disease #Monoclonal antibodies #Psilocybin #UK

DDW Highlights: 14 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More

#Podcasts

#Ajna Biosciences #Autism #Neuroscience

The promise of a botanical approach to autism

DDW Editor Reece Armstrong speaks to Joel Stanley, CEO of Ajna BioSciences, about the challenges of developing therapies for autism and why a multi-compound approach may be key to treating symptoms.  RA: What are the challenges of discovering and developing effective therapies for autism?   JS: Autism is an incredibly broad spectrum, which makes it fundamentally different from… Read More

#Exclusive Content

#Clinical trial #GLP-1 #Obesity #Weight loss

What’s the outlook for GLP-1 therapeutics?

Is the honeymoon period over for GLP-1s or is the market yet to reach its full potential? Diana Turner asks what will differentiate the next generation of these peptide analogues.  Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), which is also a GIP (glucose-dependent insulinotropic polypeptide) receptor, have… Read More

#Exclusive Content

#Biotech #Investment #LSX Europe #Start-ups

LSX Lisbon 2026: Highlights

Lu Rahman shares some of the stand-put momenta at this year’s LSX World Congress in Lisbon.   LSX World Congress Europe has always been a favourite of the DDW team. Bringing together networking, investment, pharma, start-ups and venture capital, the event offers insight into the workings of wider life science funding and investment, as well market opportunities and challenges. This year’s event… Read More

#Exclusive Content

European Commission
#AbbVie #European Commission #Follicular lymphoma #Genmab

EC grants marketing authorisation to lymphoma therapy 

The European Commission (EC) has granted marketing authorisation for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of relapsed or refractory follicular lymphoma.  The combination regimen, developed by AbbVie and Genmab for the treatment of adult patients, is the first and only bispecific-based therapy approved in Europe for the… Read More

#News #Regulatory

Novartis head office
#Biotech #Mergers and acquisitions #Myricx Bio #Novartis

Novartis acquires ADC developer Myricx Bio 

UK biotech Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion.  The companies say the acquisition advances antibody-drug conjugate (ADC) innovation by bringing together the strengths of Novartis in oncology with Myricx Bio’s two lead ADC assets and next-generation first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform, having potential impact across multiple… Read More

#Business & Investment #News

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford

DDW Highlights: 7 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More

#Podcasts

Modern medical science laboratory
#AI #France #spatial

Bioptimus partners with French cancer research organisation 

AI tech company Bioptimus has signed a partnership with one of France’s leading academic cancer research organisations in efforts to build an AI model of biology.  The partnership with the Fédération Francophone de Cancérologie Digestive (FFCD) will grant Bioptimus access to a unique cohort of deeply phenotyped clinical trial data from more than 3,000 gastrointestinal (GI)… Read More

#Cancer Research #News

#European Commission #European Union #Muscular dystrophy

Approval makes spinal muscular atrophy cream available in EU 

The European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA).  Itvisma can now be used in the European Union by children two years and older, teens and adults living with 5q SMA with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene.  The… Read More

#News #Regulatory

Dollar sign on a tablet
#Clinical trial #Drug development #Drug discovery #Investment

The changing landscape for drug discovery investment

As DDW launches its new event series Drug Discovery Innovators & Investors, Lu Rahman looks at the challenges and opportunities that exist for both drug developers and investors looking to bring a new drug to market.  It’s no news that the discovery and development of a new drug is not only costly and lengthy - over $1… Read More

#Business & Investment #Exclusive Content

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Gene therapy #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford #University of Queensland

This week in Drug Discovery (29 June – 3 July) 

News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW.  This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.  The… Read More

#News

The European Medicines Agency building
#Atopic dermatitis #CHMP #EMA #Regulatory

CHMP issues positive opinion for atopic dermatitis cream 

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a cream to treat atopic dermatitis (AD).  Opzelura (ruxolitinib) cream, developed by Incyte International for the treatment of moderate atopic dermatitis (AD), has been recommended for adult patients for whom topical corticosteroids (TCSs) and topical… Read More

#News #Regulatory

#Biotech #Exonate #Ophthalmology

Eye disease specialist Exonate appoints Hellebø as CEO 

Biotechnology company Exonate has appointed Olav Hellebø as Chief Executive Officer.  Exonate, which specialises in small-molecule therapeutics for patients with retinal vascular diseases, says Hellebø will lead the company as it strengthens its executive team and advances toward key clinical and corporate milestones, including initiating a Phase IIb clinical trial of… Read More

#News

#AbbVie #Nxera Pharma #R&D

Nxera earns $10m under terms of AbbVie collaboration 

Nxera Pharma has received $10 million after a fourth R&D milestone was met in the company’s collaboration with AbbVie.  Nxera and AbbVie entered a multi-target collaboration in 2022 to  leverage Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease.   The fourth milestone relates to the identification… Read More

#Business & Investment #News

Kidney on a chip technology
#Europe #Hansa Biopharma #License agreement #MENA

Hansa closes €115m licensing transaction for Idefirix 

Hansa Biopharma has closed a €115 million licensing transaction with SERB Pharmaceuticals for its kidney transplant drug in Europe and MENA.  Idefirix is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by the European Commission… Read More

#Business & Investment #News